Intratio
Quantitative Research
Skip to main content
AI Market Summary
Loading market intelligence...
  • Sign in
    My account
    Logout
AI 90-DAY FORECAST
BULLISH SIGNAL DETECTED
██.█% Sign up free to reveal

Krystal Biotech, Inc. (KRYS) AI Forecast

Our AI detected a significant signal for Krystal Biotech, Inc.. Create a free account to see the exact price target.

✓ Free account • ✓ 30-day free trial

$KRYS Bullish Signal Full forecast available
Sign Up Free

Krystal Biotech, Inc. (KRYS) Stock Forecast 2025

Krystal Biotech, Inc. (KRYS) AI Stock Price Forecast & Investment Analysis

Krystal Biotech, Inc. Stock Price Chart and Technical Analysis

Loading chart...

Krystal Biotech, Inc. (KRYS) - Comprehensive Stock Analysis & Investment Research

Deep dive into Krystal Biotech, Inc.'s business profile, financial performance, AI predictions, and competitive positioning to make informed investment decisions.

Analysis updated on May 22, 2026, 5:11 p.m. (UTC)

Krystal Biotech, Inc. Investment Summary

When evaluating whether Krystal Biotech, Inc. (KRYS) represents a compelling investment opportunity, investors must consider multiple factors including the company's financial health, market position, growth prospects, and what our AI-powered predictive models suggest about its near-term price trajectory.

Company Profile

Krystal Biotech, Inc. (KRYS) operates within the Life Sciences sector, specifically in the Biological Products, (No Diagnostic Substances) industry. . With a market capitalization of $9 billion, the company is a mid-cap stock that typically offers a balance between growth potential and established business operations.

Financial Performance Analysis

Our comprehensive financial analysis covers Krystal Biotech, Inc.'s revenue, profitability metrics, balance sheet strength, and cash flow generation...

AI Price Predictions

Get AI-powered 7-day, 30-day and 90-day price forecasts for Krystal Biotech, Inc. along with confidence scores and detailed analysis...

Investment Considerations

Expert analysis of whether Krystal Biotech, Inc. is suitable for your investment objectives, risk tolerance, and time horizon...

Continue Reading Full Analysis

Get the complete investment breakdown for Krystal Biotech, Inc.

Sign Up Free
Corporate Identity

Krystal Biotech, Inc. (Stock Symbol: KRYS) is a prominent company operating within the Life Sciences sector, with a specific focus on the Biological Products, (No Diagnostic Substances) industry. The company's shares are publicly traded on the Nasdaq exchange.

Leadership & Workforce

Detailed information about Krystal Biotech, Inc.'s leadership team, workforce size, and organizational structure...

Market Classification

Market capitalization analysis and stock classification (mega-cap, large-cap, mid-cap, small-cap) for Krystal Biotech, Inc....

Sector & Industry Analysis

In-depth sector dynamics and industry context for Krystal Biotech, Inc....

Unlock Full Company Profile

Get complete details about Krystal Biotech, Inc.

Sign Up Free
Revenue & Growth Analysis

Krystal Biotech, Inc. generates annual revenues of $417 million , representing an emerging company in its growth phase.

Profitability Metrics

Net profit margin, gross margin, and operating margin analysis for Krystal Biotech, Inc....

Market Valuation

P/E ratio, price-to-book, and valuation multiples for Krystal Biotech, Inc....

Return Metrics

Return on equity (ROE), return on assets (ROA), and capital efficiency for Krystal Biotech, Inc....

Unlock Financial Analysis

Get complete financial metrics for Krystal Biotech, Inc.

Sign Up Free
AI ANALYSIS AVAILABLE

Unlock Krystal Biotech, Inc.'s AI Price Forecast

Join 10,000+ investors using our 67%+ accurate AI predictions

4,000+ Stocks Analyzed
67%+ Accuracy Rate
Daily Updates
Start 30-Day Free Trial →

✓ 30-day free trial • ✓ Cancel anytime

Strategic Market Position

Krystal Biotech, Inc. strategically competes in the highly dynamic Biological Products, (No Diagnostic Substances) marketplace. As a mid-cap company, it occupies an attractive position balancing growth potential with established operations. Mid-caps often represent the 'sweet spot' for investors seeking companies that have proven their business models but still have meaningful runway for expansion. These companies are large enough to have competitive advantages but nimble enough to adapt quickly to market changes.

Industry Competitive Landscape

Krystal Biotech, Inc. competes within the Life Sciences sector, navigating the competitive dynamics and market forces specific to this industry. The company's competitive position depends on its ability to differentiate through product quality, cost efficiency, customer relationships, or other strategic advantages relevant to its specific market segment.

Operational Efficiency

The company shows positive operational efficiency through free cash flow generation of $237 million annually . Positive free cash flow indicates the business generates more cash than required for operations and capital investments, providing resources for growth initiatives or shareholder returns.

Asset Utilization Efficiency

Asset turnover ratio of 0.30x indicates lower asset turnover that may reflect the industry's capital-intensive nature or potentially underutilized assets. Companies with low turnover typically depend on strong margins to generate adequate returns on capital.

Financial Strength & Leverage

Current ratio of 9.46 demonstrates strong short-term liquidity with current assets significantly exceeding current liabilities. This provides a substantial buffer for meeting near-term obligations and handling unexpected financial needs.

Krystal Biotech, Inc. (KRYS) Fundamental Analysis & Insider Trading Data (Quarterly Financial Reports)

Comprehensive quarterly financial data, earnings trends, insider transactions, and institutional holdings for Krystal Biotech, Inc. stock analysis.

Deep dive into Krystal Biotech, Inc.'s financial health, valuation metrics, and operational efficiency to make informed investment decisions.

Understanding Valuation Metrics

What these metrics mean: Valuation metrics help determine if Krystal Biotech, Inc. stock is fairly priced compared to its earnings, assets, and market position.

How to read them: Lower P/E ratios may indicate undervalued stocks, while higher ratios suggest growth expectations. P/B ratio compares market value to book value.

For Krystal Biotech, Inc.: With a P/E ratio of 39.80, the market highly values future growth prospects.

P/E Ratio 39.80x
P/B Ratio 7.01x
Market Cap $8.96B
Book Value/Share $43.37
Revenue/Share $14.18
FCF/Share $8.06
Understanding Profitability Metrics

What these metrics mean: These ratios measure how efficiently Krystal Biotech, Inc. converts revenue into profit and generates returns for shareholders.

How to read them: Higher ROE/ROA indicate better management efficiency. Margin percentages show profit at different operational levels.

For Krystal Biotech, Inc.: An ROE of -2.0% indicates room for improvement in shareholder value creation.

ROE -2.0%
ROA -1.9%
ROIC -1.0%
Understanding Financial Health Metrics

What these metrics mean: These ratios assess Krystal Biotech, Inc.'s ability to meet short-term obligations and manage debt levels effectively.

How to read them: Current ratio >2 is generally good, Quick ratio >1 shows strong liquidity. Lower D/E ratios indicate conservative debt management.

For Krystal Biotech, Inc.: A current ratio of 9.46 indicates strong liquidity.

Current Ratio 9.46x
Quick Ratio 9.06x
D/E Ratio 0.09x
Financial Leverage 1.09x
Interest Coverage 7.3x
Working Capital $912M
Understanding Cash Flow Metrics

What these metrics mean: Cash flow metrics reveal Krystal Biotech, Inc.'s ability to generate cash from operations and fund growth initiatives.

How to read them: Positive operating cash flow is crucial. Free cash flow shows money available for dividends, buybacks, or investments.

For Krystal Biotech, Inc.: Free cash flow of $237M provides flexibility for shareholder returns and growth investments.

Operating Cash Flow -$7M
Free Cash Flow $237M
Capital Spending $244M
FCF/Sales 56.9%
CapEx/Sales 58.6%
Understanding Operational Efficiency Metrics

What these metrics mean: These ratios measure how effectively Krystal Biotech, Inc. uses its assets and manages working capital.

How to read them: Higher turnover ratios indicate efficient asset utilization. Shorter collection periods show effective credit management.

For Krystal Biotech, Inc.: An asset turnover of 0.30x suggests room for improvement in asset utilization.

Asset Turnover 0.30x
Receivables Turnover 3.3x
Fixed Assets Turnover 2.7x
Days Sales Outstanding 111 days
Understanding Financial Statement Data

What these metrics mean: Key figures from Krystal Biotech, Inc.'s income statement and balance sheet showing absolute financial performance.

How to read them: Revenue shows business scale, while margins indicate profitability. Balance sheet items reveal financial structure.

For Krystal Biotech, Inc.: With annual revenue of $417M, Krystal Biotech, Inc. demonstrates solid business size.

Income Statement
Total Revenue $417M
Operating Income -$13M
Net Income -$26M
R&D Expense $8M
Balance Sheet Highlights (% Of Assets)
Total Current Assets 1020%
Cash & Short-term Investments 501%
Total Liabilities 120%
Short-term Debt 104%
Accounts Receivable 127%
Inventory 43%
Dividend & Shareholder Information
Shares Outstanding 29M

Latest Krystal Biotech, Inc. Stock News & Market Analysis

Breaking news, analyst reports, and market updates affecting Krystal Biotech, Inc. (KRYS) stock price and investment outlook.

More news available

Sign up free to read all 10 news articles and stay updated on market developments.

Sign Up Free to Read More

Krystal Biotech, Inc. Competitors & Peer Analysis - Life Sciences Sector

Comparative analysis of Krystal Biotech, Inc. against industry peers and competitors in the Life Sciences sector, featuring AI-powered forecasts and key financial metrics.

Company Ticker Symbol 90-Day AI Forecast Market Cap (USD M) P/E Ratio P/B Ratio
Acumen Pharmaceuticals, Inc. ABOS ██% $180M x 2.1x
Abpro Holdings, Inc. ABP ██% $310K x 0.0x
Abpro Holdings, Inc. ABPO ██% $1M x x
Arcellx, Inc. ACLX ██% $6.73B x 16.7x
Alpha Cognition Inc. ACOG ██% $127M x 2.2x
Adaptimmune Therapeutics Plc ADAP ██% $77M -13.2x -11.8x
Adma Biologics, Inc. ADMA ██% $1.97B 11.9x 5.0x
Adaptive Biotechnologies Corp ADPT ██% $2.21B x 10.2x
Adverum Biotechnologies, Inc. ADVM ██% $95M -1.8x 2.2x
Agenus Inc AGEN ██% $122M 1.9x x
Agentix Corp. AGTX ██% $1M x x
Aim Immunotech Inc. AIM ██% $4M x 1.8x
Aim Immunotech Inc. AIMI ██% $1M x x
Alector, Inc. ALEC ██% $245M x 23.6x
Aligos Therapeutics, Inc. ALGS ██% $35M x 1.1x
Allogene Therapeutics, Inc. ALLO ██% $676M x 2.4x
Alvotech ALVO ██% $1.05B x x
Amgen Inc AMGN ██% $182.11B 23.4x 19.8x
Apogee Therapeutics, Inc. APGE ██% $6.17B x x
Aptose Biosciences Inc. APTOF ██% $4M x x
Argenx Se ARGX ██% $50.51B x x
Armata Pharmaceuticals, Inc. ARMP ██% $301M x x
Artiva Biotherapeutics, Inc. ARTV ██% $388M x 4.4x
Leonabio, Inc. ATHA ██% $23M -0.2x 0.9x
Atara Biotherapeutics, Inc. ATRA ██% $80M x x
Atyr Pharma Inc ATYR ██% $52M x 0.9x
Aura Biosciences, Inc. AURA ██% $791M x 7.4x
Autolus Therapeutics Plc AUTL ██% $439M x 4.0x
Anavex Life Sciences Corp. AVXL ██% $251M x 2.0x
Bioatla, Inc. BCAB ██% $6M x x
Biocardia, Inc. BCDA ██% $10M x x
Brainstorm Cell Therapeutics Inc. BCLI ██% $9M x x
Biocryst Pharmaceuticals Inc BCRX ██% $2.13B x x
Black Diamond Therapeutics, Inc. BDTX ██% $203M x 2.0x
Beam Therapeutics Inc. BEAM ██% $2.84B x 2.4x
Biogen Inc. BIIB ██% $27.89B 20.3x 1.5x
Biontech Se BNTX ██% $22.99B x x
Cabaletta Bio, Inc. CABA ██% $602M x 5.8x
Candel Therapeutics, Inc. CADL ██% $581M x 4.2x
C4 Therapeutics, Inc. CCCC ██% $366M x 1.6x
Cidara Therapeutics, Inc. CDTX ██% $6.49B -1.0x 15.4x
Creative Medical Technology Holdings, Inc. CELZ ██% $8M x 1.4x
Cero Therapeutics Holdings, Inc. CERO ██% $900K x x
Cullinan Therapeutics, Inc. CGEM ██% $859M x 2.4x
Compugen Ltd CGEN ██% $247M 3.5x 2.4x
Cg Oncology, Inc. CGON ██% $5.68B x 5.2x
Cognition Therapeutics Inc CGTX ██% $112M x 3.7x
Coherus Oncology, Inc. CHRS ██% $242M 1.3x 3.1x
Calidi Biotherapeutics, Inc. CLDI ██% $4M x 0.8x
Cellectis S.A. CLLS ██% $354M x x
Compass Therapeutics, Inc. CMPX ██% $348M x 1.9x
Mosaic Immunoengineering Inc. CPMV ██% $5M x x
Caribou Biosciences, Inc. CRBU ██% $142M -1.5x 1.0x
Cardiff Oncology, Inc. CRDF ██% $122M x 3.5x
Cardiol Therapeutics Inc. CRDL ██% $151M x x
Curis Inc CRIS ██% $20M x 1.5x
Crispr Therapeutics Ag CRSP ██% $4.81B x 2.7x
Champions Oncology, Inc. CSBR ██% $83M x 19.3x
Cel Sci Corp CVM ██% $21M x 3.1x
Dbv Technologies S.A. DBVT ██% $1.10B x 6.5x
Dbv Technologies S.A. DBVTF ██% $10K x 0.0x
Ginkgo Bioworks Holdings, Inc. DNA ██% $498M x 1.1x
Denali Therapeutics Inc. DNLI ██% $3.06B x 3.3x
Precision Biosciences Inc DTIL ██% $185M x 2.4x
Dyadic International Inc DYAI ██% $27M x x
Editas Medicine, Inc. EDIT ██% $261M x 59.3x
Eloxx Pharmaceuticals, Inc. ELOX ██% $5M x x
Elutia Inc. ELUT ██% $52M 1.0x 2.3x
Engene Therapeutics Inc. ENGN ██% $116M x 0.4x
Entera Bio Ltd. ENTX ██% $59M x 5.5x
Viskase Holdings, Inc. ENZN ██% $38M x 0.2x
Estrella Immunopharma, Inc. ESLA ██% $48M x x
Evaxion A/S EVAX ██% $34M x x
Exelixis, Inc. EXEL ██% $12.60B 15.1x 6.5x
Exozymes Inc. EXOZ ██% $80M x 52.2x
Fate Therapeutics Inc FATE ██% $244M x 1.4x
4d Molecular Therapeutics, Inc. FDMT ██% $454M x 1.0x
Fennec Pharmaceuticals Inc. FENC ██% $344M x 9.1x
Finch Therapeutics Group, Inc. FNCH ██% $12M 0.5x 0.9x
Finch Therapeutics Group, Inc. FNCHQ ██% $12M 0.5x 0.8x
Futuretech Ii Acquisition Corp. FTII ██% $52M x x
Futuretech Ii Acquisition Corp. FTIIU ██% $14M x -0.8x
Gilead Sciences, Inc. GILD ██% $162.08B 17.6x 6.9x
Monte Rosa Therapeutics, Inc. GLUE ██% $1.59B x 3.1x
Genenta Science S.P.A. GNTA ██% $14M x 1.1x
Green Planet Bio Engineering Co. Ltd. GPLB ██% N/A x x
Greenland Mines Ltd GRML ██% $47M x 0.9x
Halozyme Therapeutics, Inc. HALO ██% $8.12B 23.3x 37.0x
Humacyte, Inc. HUMA ██% $226M x 19.5x
Immunitybio, Inc. IBRX ██% $8.11B x x
Inhibikase Therapeutics, Inc. IKT ██% $230M x 1.4x
Imagenebio, Inc. IMA ██% $62M x 0.5x
Immunocore Holdings Plc IMCR ██% $1.52B x 3.9x
Immatics N.V. IMTX ██% $1.48B x x
Immunovant, Inc. IMVT ██% $6.96B x 8.2x
In8bio, Inc. INAB ██% $17M x 0.7x
Inhibrx Biosciences, Inc. INBX ██% $873M -6.8x 109.2x
Mink Therapeutics, Inc. INKT ██% $52M x x
Inmune Bio, Inc. INMB ██% $38M x 2.0x
Intensity Therapeutics, Inc. INTS ██% $12M x 1.2x
Iovance Biotherapeutics, Inc. IOVA ██% $1.62B x 2.3x
Century Therapeutics, Inc. IPSC ██% $409M x 1.5x
Invivyd, Inc. IVVD ██% $314M x 1.6x
Jasper Therapeutics, Inc. JSPR ██% $24M x 7.2x
Kalaris Therapeutics, Inc. KLRS ██% $118M x 1.7x
Klotho Neurosciences, Inc. KLTO ██% $56M x 5.7x
Kodiak Sciences Inc. KOD ██% $2.33B x 20.7x
Krystal Biotech, Inc. KRYS ██% $8.96B 39.8x 7.0x
Kymera Therapeutics, Inc. KYMR ██% $6.62B x 4.3x
Kyverna Therapeutics, Inc. KYTX ██% $539M x 2.8x
Ladrx Corp LADX ██% $20K x 0.1x
Lineage Cell Therapeutics, Inc. LCTX ██% $329M x 6.1x
Lenz Therapeutics, Inc. LENZ ██% $236M x 1.0x
Atyr Pharma Inc LIFE ██% $2.03B x 35.1x
Liminatus Pharma, Inc. LIMN ██% $11M x x
Leonabio, Inc. LONA ██% $95M x 1.9x
Lexeo Therapeutics, Inc. LXEO ██% $387M x 1.7x
Maze Therapeutics, Inc. MAZE ██% $1.43B x 4.2x
Mesoblast Ltd MESO ██% $1.94B x x
Meiragtx Holdings Plc MGTX ██% $879M x x
Metagenomi Therapeutics, Inc. MGX ██% $49M x 0.4x
Molecular Partners Ag MOLN ██% $153M x x
Moderna, Inc. MRNA ██% $18.76B x 2.5x
Neurocrine Biosciences Inc NBIX ██% $15.64B 23.4x 4.6x
Nkgen Biotech, Inc. NKGN ██% $2M -0.1x -0.2x
Neumora Therapeutics, Inc. NMRA ██% $333M x 4.7x
Novavax Inc NVAX ██% $1.48B x x
Ocugen, Inc. OCGN ██% $457M x 78.7x
Outlook Therapeutics, Inc. OTLK ██% $40M x x
Palisade Bio, Inc. PALI ██% $337M x 2.6x
Passage Bio, Inc. PASG ██% $17M x 1.4x
Vaxcyte, Inc. PCVX ██% $6.84B x 2.3x
Biomx Inc. PHGE ██% $7M x x
Pluri Inc. PLUR ██% $24M x x
Protalix Biotherapeutics, Inc. PLX ██% $162M 10.6x 2.4x
Pharmacyte Biotech, Inc. PMCB ██% $9M x 0.2x
Prime Medicine, Inc. PRME ██% $533M x 7.0x
Prokidney Corp. PROK ██% $529M x x
Pelthos Therapeutics Inc. PTHS ██% $91M x 2.6x
Qiagen N.V. QGEN ██% $7.57B x 2.0x
Quince Therapeutics, Inc. QNCX ██% $21M 2.4x 1.3x
Qrons Inc. QRON ██% $150K x x
Replimune Group, Inc. REPL ██% $416M x 2.0x
Repligen Corp RGEN ██% $6.39B 124.4x 3.0x
Regenxbio Inc. RGNX ██% $348M x 16.5x
Relay Therapeutics, Inc. RLAY ██% $2.58B x 4.0x
Revolution Medicines, Inc. RVMD ██% $30.77B x 20.5x
Recursion Pharmaceuticals, Inc. RXRX ██% $1.65B x 1.6x
Sab Biotherapeutics, Inc. SABS ██% $291M x 1.3x
Sana Biotechnology, Inc. SANA ██% $850M x 7.1x
Scilex Holding Co SCLX ██% $42M x x
Scinai Immunotherapeutics Ltd. SCNI ██% $2M x 0.3x
Sangamo Therapeutics, Inc SGMO ██% $62M x x
Solid Biosciences Inc. SLDB ██% $640M x 1.7x
Silexion Therapeutics Corp SLXN ██% $2M x 6.8x
Senti Biosciences Holdings, Inc. SNTI ██% $31M x 12.0x
Scholar Rock Holding Corp SRRK ██% $5.68B x 20.6x
Surrozen, Inc./De SRZN ██% $311M x x
Sutro Biopharma, Inc. STRO ██% $507M x x
Protara Therapeutics, Inc. TARA ██% $262M x 1.5x
Tarsus Pharmaceuticals, Inc. TARS ██% $2.73B x 7.8x
Tc Biopharm (Holdings) Plc TCBPY ██% $10K x 0.0x
Tscan Therapeutics, Inc. TCRX ██% $67M x 0.7x
Bio-Techne Corp TECH ██% $7.10B 64.8x 3.4x
Tectonic Therapeutic, Inc. TECX ██% $541M x 2.4x
Instil Bio, Inc. TIL ██% $54M x 0.5x
Tenaya Therapeutics, Inc. TNYA ██% $170M x 1.6x
Tourmaline Bio, Inc. TRML ██% $1.23B -3.5x 4.8x
Taysha Gene Therapies, Inc. TSHA ██% $1.57B x 7.4x
Titan Pharmaceuticals Inc TTNP ██% $6M -0.5x 2.2x
Tevogen Bio Holdings Inc. TVGN ██% $41M x x
Twist Bioscience Corp TWST ██% $3.29B x 7.2x
Voyager Acquisition Corp./Cayman Islands VACH ██% $364M 54.0x x
Voyager Acquisition Corp./Cayman Islands VACHU ██% $68M 6.7x 0.0x
Valneva Se VALN ██% $546M x x
Vericel Corp VCEL ██% $1.80B 84.0x 5.1x
Vir Biotechnology, Inc. VIR ██% $1.43B x 1.8x
Vivosim Labs, Inc. VIVS ██% $3M x 0.8x
Vor Biopharma Inc. VOR ██% $805M x x
Vaxart, Inc. VXRT ██% $150M 4.0x 1.6x
Voyager Therapeutics, Inc. VYGR ██% $214M x 1.2x
Windtree Therapeutics Inc /De/ WINT ██% $670K x x
X4 Pharmaceuticals, Inc XFOR ██% $371M x 2.2x
Zeo Scientifix, Inc. ZEOX ██% $14M x x
Zivo Bioscience, Inc. ZIVO ██% $14M x x
Zura Bio Ltd ZURA ██% $410M x 1.9x
Reveal all forecasts See exact % predictions for all competitors
Sign up free

Frequently Asked Questions - Krystal Biotech, Inc. Stock Forecast

How accurate are Krystal Biotech, Inc. stock predictions?

Our AI model shows a 8500% Spearman correlation coefficient for KRYS predictions, based on advanced machine learning algorithms trained on over 10 years of market data. This measures the strength of the monotonic relationship between predicted and actual price movements.

What factors influence Krystal Biotech, Inc. stock price forecasts?

Our analysis considers Krystal Biotech, Inc.'s financial metrics, Life Sciences sector trends, market sentiment, technical indicators, earnings data, and macroeconomic factors affecting stock performance.

Is Krystal Biotech, Inc. a good investment in 2025?

Based on our AI analysis, Krystal Biotech, Inc. shows potential for various market scenarios. Consider your risk tolerance, investment timeline, and portfolio diversification before making investment decisions.

How often are Krystal Biotech, Inc. forecasts updated?

Krystal Biotech, Inc. stock forecasts are updated daily using real-time market data, ensuring you receive the most current AI-powered predictions and investment insights.

Want a simpler view of Krystal Biotech, Inc.?

View simplified analysis on AI Stock Finder →

My Portfolio

Investment Dashboard

Loading your portfolio...